» Articles » PMID: 17297466

Cell-specific Responses to Loss of Cyclin-dependent Kinases

Overview
Journal Oncogene
Date 2007 Feb 14
PMID 17297466
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Inactivation of cyclin-dependent kinases (Cdks) and/or cyclins in mice has changed our view of cell cycle regulation. In general, cells are far more resistant to the loss of Cdks than originally anticipated, suggesting widespread compensation among the Cdks. Early embryonic cells are, so far, not sensitive to the lack of multiple Cdks or cyclins. In contrast, differentiated cells are more dependent on Cdk/cyclin complexes and the functional redundancy is more limited. Our challenge is to better understand these cell-type specific differences in cell cycle regulation that can be used to design efficient cancer therapy. Indeed, tumor cells seem to respond to inhibition of Cdk activities, however, with different outcome depending on the tumor cell type. Tumor cells share some proliferation features with stem cells, but appear more sensitive to loss of Cdk activity, somewhat resembling differentiated cells. We summarize the current knowledge of cell cycle regulation in different cell types and highlight their sensitivity to the lack of Cdk activities.

Citing Articles

Identification PMS1 and PMS2 as potential meiotic substrates of CDK2 activity.

Palmer N, Talib S, Goh C, Biswas K, Sharan S, Kaldis P PLoS One. 2023; 18(3):e0283590.

PMID: 36952545 PMC: 10035876. DOI: 10.1371/journal.pone.0283590.


The Prognostic Role of CDK9 in Bladder Cancer.

Borowczak J, Szczerbowski K, Maniewski M, Zdrenka M, Slupski P, Antosik P Cancers (Basel). 2022; 14(6).

PMID: 35326643 PMC: 8945910. DOI: 10.3390/cancers14061492.


Role of cyclin-dependent kinase 2 in the progression of mouse juvenile cystic kidney disease.

Zhang J, Burgess J, Stepanova D, Saravanabavan S, Wong A, Kaldis P Lab Invest. 2020; 100(5):696-711.

PMID: 31915367 DOI: 10.1038/s41374-019-0360-4.


The essentiality landscape of cell cycle related genes in human pluripotent and cancer cells.

Viner-Breuer R, Yilmaz A, Benvenisty N, Goldberg M Cell Div. 2020; 14:15.

PMID: 31889988 PMC: 6927170. DOI: 10.1186/s13008-019-0058-4.


Safety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trials.

Guo L, Hu Y, Chen X, Li Q, Wei B, Ma X Cancer Med. 2019; 8(4):1389-1400.

PMID: 30897298 PMC: 6488107. DOI: 10.1002/cam4.1970.